Company: SHPH
Filing Date: 2025-03-13
Form Type: 8-K
Source: 0001493152-25-010211
Chunk: 2

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-13
Form: 8-K
Item: Item 3.01
Chunk 2
---
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As
disclosed previously, on September 10, 2024, the Company received a written notice (the “ Notice”) from The Nasdaq Stock Market
LLC (“ Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Rule 5550(b)(1), the minimum stockholders’
equity requirement of $2,500,000 for continued listing on the Nasdaq (the “ Minimum Equity Requirement”).

In
response to the Notice, the Company submitted its plan of regain compliance to Nasdaq (the “ Plan”) and on November 26, 2024,
the Company received notice from Nasdaq that it had accepted the Plan. In accordance with the Plan, the Company is required to complete
an equity offering sufficient to bring the Company’s stockholders’ equity above the Minimum Equity Requirement and be able
to demonstrate that it is in compliance in its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “ First Quarter
Form 10-Q”).

On
March 13, 2025, following the Company’s receipt of approximately $5.2 million in net proceeds from the Offering, the Company believes
it is now in compliance with the Minimum Equity Requirement and will be able to demonstrate such compliance in its First Quarter
Form 10-Q.

Nasdaq
will continue to monitor the Company’s ongoing compliance with the Minimum Equity Requirement and, if at the time of the filing
of its First Quarter Form 10-Q the Company does not evidence compliance, it may be subject to delisting.

Item
7.01 Regulation FD Disclosure